Abstract
Acute and chronic inflammatory demyelinating polyneuropathy (AIDP and CIDP) are two types of immune-mediated neuropathies in which abnormal cellular or humoral immune responses have been observed. Although dysregulation of several cytokines has been detected in these disorders, expression of interleukin 38 (IL-38) has not yet been assessed in AIDP and CIDP. In the current study, we evaluated serum concentrations of this member of the IL-1 family of cytokines in 24 patients with CIDP, 13 patients with AIDP and 27 healthy subjects. We detected higher levels of IL-38 in CIDP patients compared with controls. When assessing study subgroups based on gender, there were no significant differences in IL-38 levels among the three female subgroups (P = 0.14). However, the difference among male subgroups was significant (P = 0.010). A Tukey test showed significant differences between male CIDP patients and male controls (P = 0.014). Considering the proposed anti-inflammatory role of IL-38, higher levels of this cytokine in CIDP might reflect the presence of a compensatory mechanism to reduce inflammatory processes in these patients. Further longitudinal assessment of this cytokine is need to test this hypothesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ali ZPM, Taheri M, Sangsefidi S, Arsang-Jang S, Mazdeh M, Zamani A, Ghafouri-Fard S, Eftekharian MM (2020) Evaluation of expression of STAT genes in immune-mediated polyneuropathies. J Mol Neurosci
Boutet MA, Bart G, Penhoat M, Amiaud J, Brulin B, Charrier C, Morel F, Lecron JC, Rolli-Derkinderen M, Bourreille A, Vigne S, Gabay C, Palmer G, Le Goff B, Blanchard F (2016) Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin Exp Immunol 184:159–173
Chou CT, Timms AE, wei JC, Tsai WC, Wordsworth BP, Brown MA (2006) Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Ann Rheum Dis 65:1106–1109
Khattab FM, Khater EM, Ibraheem HA (2019) Serum levels of interleukin-38 in sufferers with atopic eczema. Egypt J Derm Venerol 39:66
Kieseier BC, Wiendl H, Hartung HP (2006) The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol 19:433–436
Koller H, Kieseier BC, Jander S, Hartung HP (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352:1343–1356
Lehmann HC, Meyer ZU, Horste G, Kieseier BC, Hartung H-P (2009) Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord 2:261–281
Li J, Liu L, Rui W, Li X, Xuan D, Zhen GS, Yu Y, Zhang J, Kong N, Zhu X, Zou H, Wan W, Xue Y (2017) New interleukins in psoriasis and psoriatic arthritis patients: the possible roles of Interleukin-33 to Interleukin-38 in disease activities and bone erosions. Dermatology 233:37–46
Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace AM, Hansen D, Schweighofer K, Mize NK, Ford JE (2001) Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 276:20597–20602
Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014–1022
Peng J, Zhang H, Liu P, Chen M, Xue B, Wang R, Shou J, Qian J, Zhao Z, Xing Y, Liu H (2018) IL-23 and IL-27 levels in serum are associated with the process and the recovery of Guillain-Barré syndrome. Sci Rep 8:2824–2824
Press R, Deretzi G, Zou LP, Zhu J, Fredman P, Lycke J, Link H (2001) IL-10 and IFN-gamma in Guillain-Barre syndrome. Network members of the Swedish epidemiological study group. J Neuroimmunol 112:129–138
Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) (1991) Report from an ad hoc Subcommittee of the American Academy of neurology AIDS task force. Neurology 41:617–618
Rudloff I, Godsell J, Nold-Petry CA, Harris J, Hoi A, Morand EF, Nold MF (2015) Brief report: Interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol 67:3219–3225
Schaefer TM, Wright JA, Pioli PA, Wira CR (2005) IL-1β-mediated proinflammatory responses are inhibited by estradiol via down-regulation of IL-1 receptor type I in uterine epithelial cells. J Immunol 175:6509–6516
Singer CF, Kronsteiner N, Hudelist G, Marton E, Walter I, Kubista M, Czerwenka K, Schreiber M, Seifert M, Kubista E (2003) Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1alpha protein secretion is correlated with malignant phenotype. Clin Cancer Res 9:4877–4883
Takenaka SI, Kaieda S, Kawayama T, Matsuoka M, Kaku Y, Kinoshita T, Sakazaki Y, Okamoto M, Tominaga M, Kanesaki K, Chiba A, Miyake S, Ida H, Hoshino T (2015) IL-38: a new factor in rheumatoid arthritis. Biochem Biophys Rep 4:386–391
Van De Veerdonk FL, Netea MG (2013) New insights in the immunobiology of IL-1 family members. Front Immunol 4:167
Van De Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG, Joosten LA, Van Der Meer JW, Hao R, Kalabokis V, Dinarello CA (2012) IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 109:3001–3005
Van Der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG (2001) Diagnostic and classification criteria for the Guillain-Barre syndrome. Eur Neurol 45:133–139
Acknowledgements
The current study was supported by a grant from Hamadan University of Medical Sciences.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ali, Z.P.M., Ghafouri-Fard, S., Komaki, A. et al. Assessment of IL-38 Levels in Patients with Acquired Immune-Mediated Polyneuropathies. J Mol Neurosci 70, 1385–1388 (2020). https://doi.org/10.1007/s12031-020-01558-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-020-01558-z